These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21448467)

  • 21. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D; Manni A; Iaffaldano A; Trojano M
    CNS Drugs; 2020 Jan; 34(1):65-92. PubMed ID: 31898276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ; O'Connor PW
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
    Thöne J; Ellrichmann G
    Drug Healthc Patient Saf; 2013; 5():37-47. PubMed ID: 23459383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newer agents in the treatment of multiple sclerosis.
    Pawate S; Bagnato F
    Neurologist; 2015 Apr; 19(4):104-17. PubMed ID: 25888198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune therapy of multiple sclerosis--future strategies.
    Meuth SG; Göbel K; Wiendl H
    Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
    J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.
    Oh J; Gagné-Brosseau MS; Guenette M; Larochelle C; Lemieux F; Menon S; Morrow SA; Poliquin-Lasnier L; Roy-Hewitson C; Rush C; Trudelle AM; Giacomini PS
    Can J Neurol Sci; 2018 May; 45(3):304-312. PubMed ID: 29756588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral disease-modifying treatments for multiple sclerosis: the story so far.
    Kieseier BC; Wiendl H
    CNS Drugs; 2007; 21(6):483-502. PubMed ID: 17521228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging oral drugs for multiple sclerosis.
    Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral disease-modifying therapies for multiple sclerosis.
    Kim W; Zandoná ME; Kim SH; Kim HJ
    J Clin Neurol; 2015 Jan; 11(1):9-19. PubMed ID: 25628732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of laquinimod in multiple sclerosis: current status.
    Haggiag S; Ruggieri S; Gasperini C
    Ther Adv Neurol Disord; 2013 Nov; 6(6):343-52. PubMed ID: 24228070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.